Spyre Therapeutics (NASDAQ: SYRE) announced the launch of its SPY772 program and the initiation of the Phase 2 SKYLIGHT trial in hidradenitis suppurativa (HS). Sector: Biotechnology / Immunology Key Highlights 🧬 Launched the SPY772 program 🧪 Initiated Phase 2 SKYLIGHT trial 🎯 Targeting hidradenitis suppurativa 🚀 Expands Spyre's clinical development pipeline Why It Matters The new program expands Spyre's immunology pipeline and adds another clinical-stage opportunity targeting inflammatory disease. Read More: https://www.thinksabio.com/reports/isr/SYRE